Headline results for the fourth quarter:
|Revenue||JPY 312.3 billion ($2.9 billion)||+3.6|
|Sales||JPY 5.4 billion ($50 million)||-82.5%|
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
Astellas indicated that the impact of the COVID-19 pandemic on its financial results for fiscal 2019 have been "immaterial."
Astellas said that as "it is difficult to assess properly the impact [of COVID-19] on financial results at this point, the impact has not been incorporated" into its guidance for fiscal 2020. The Japanese drugmaker expects full-year sales of JPY 1.3 trillion ($12.1 billion) for fiscal 2020, down 1.4% from fiscal 2019, with profit of JPY 202 billion ($1.9 billion), which is 3.4% higher.
The Japanese drugmaker disclosed that during the quarter, it discontinued Phase II trials of reldesemtiv in spinal muscular atrophy and in amyotrophic lateral sclerosis. It has also ended mid-stage trials of ASP4345 in cognitive impairment associated with schizophrenia, and of ASP0819 in fibromyalgia.
To read more Top Story articles, click here.